Respiratory infections due to Pseudomonas aeruginosa remain a significant health problem for immunocompromised hosts and cystic fibrosis (CF) patients. Efforts to control these infections with antibiotics and better pulmonary therapy have done little to reduce the high degree of mortality related to P. aeruginosa pneumonia. Immunotherapeutic interventions with active vaccination or passive therapy may impact significantly on this condition. It is the long term goal of this proposal to understand the role of antibodies and lymphocytes in protection against P. aeruginosa lung infections. Two murine models will be employed: one is a neutropenic mouse, which dies from P. aeruginosa pneumonia following intratracheal instillation of fewer than 20 organisms; the other is a chronic lung infection following intratracheal instillation of bacteria encased in agar beads. We will treat animals prior to infection with polyclonal and monoclonal human antibodies, or monoclonal mouse antibodies, to evaluate the role of antibodies of different immunoglobulin isotypes in protection. Another parameter to evaluate in protection and enhancement of lung clearance will be the specificity of these antibodies for different P. aeruginosa surface polysaccharide antigens. Studies are planned which will evaluate the role of T cell immunity in protection of neutropenic mice from pneumonia by adoptively transferring immune splenic and lung T cells to mice prior to challenge. The investigations planned here will also evaluate the contribution of host monokines, inter- leukin-1 and tumor necrosis factor, to the lung pathology resulting from chronic P. aeruginosa colonization. These data should provide important insights into which therapies, both active and passive immunotherapies and/or other pharacologic interventions, may have the most beneficial effect on P. aeruginosa lung infections.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI022534-06
Application #
3133740
Study Section
Bacteriology and Mycology Subcommittee 2 (BM)
Project Start
1984-12-01
Project End
1991-11-30
Budget Start
1989-12-01
Budget End
1991-11-30
Support Year
6
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02115
Stegmann, T; Schoen, P; Bron, R et al. (1993) Evaluation of viral membrane fusion assays. Comparison of the octadecylrhodamine dequenching assay with the pyrene excimer assay. Biochemistry 32:11330-7
Bron, R; Wahlberg, J M; Garoff, H et al. (1993) Membrane fusion of Semliki Forest virus in a model system: correlation between fusion kinetics and structural changes in the envelope glycoprotein. EMBO J 12:693-701
Pier, G B; Grout, M; Desjardins, D (1991) Complement deposition by antibodies to Pseudomonas aeruginosa mucoid exopolysaccharide (MEP) and by non-MEP specific opsonins. J Immunol 147:1869-76
Garner, C V; DesJardins, D; Pier, G B (1990) Immunogenic properties of Pseudomonas aeruginosa mucoid exopolysaccharide. Infect Immun 58:1835-42
Pier, G B; Small, G J; Warren, H B (1990) Protection against mucoid Pseudomonas aeruginosa in rodent models of endobronchial infections. Science 249:537-40
Pennington, J E; Small, G J (1987) Passive immune therapy for experimental Pseudomonas aeruginosa pneumonia in the neutropenic host. J Infect Dis 155:973-8
Pennington, J E (1987) Therapeutic strategies for Pseudomonas aeruginosa pneumonia in the myelosuppressed host. Antibiot Chemother 39:51-9
Pennington, J E; Small, G J; Lostrom, M E et al. (1986) Polyclonal and monoclonal antibody therapy for experimental Pseudomonas aeruginosa pneumonia. Infect Immun 54:239-44
Pennington, J E; Pier, G B; Sadoff, J C et al. (1986) Active and passive immunization strategies for Pseudomonas aeruginosa pneumonia. Rev Infect Dis 8 Suppl 4:S426-33